Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 33342-093

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 33342-093). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Rizatriptan Figure 1)

A line chart depicting the estimated probability of response over time up to 2 hours post-dose for rizatriptan benzoate tablets 5 mg and 10 mg compared to placebo. The chart shows the response rates increasing from 0% to approximately 40% for placebo, 65% for 5 mg, and 70% for 10 mg tablets.*

FDA Label Image

Figure-2 (Rizatriptan Figure 2)

A line graph depicting the estimated probability of remediation or rescue over 24 hours post-dose for rizatriptan benzoate tablets at 5 mg and 10 mg strengths compared to placebo. The horizontal axis shows hours post-dose, while the vertical axis represents the estimated probability percentage. The graph includes three lines: placebo, 5 mg tablets, and 10 mg tablets, illustrating their respective curves over time.*

FDA Label Image

Figure-3 (Rizatriptan Figure 3)

A line graph showing the estimated probability of response over time in hours post-dose for rizatriptan benzoate orally disintegrating tablets at 5 mg and 10 mg doses compared to placebo. The graph illustrates higher response probabilities for both rizatriptan doses versus placebo, with the 10 mg dose showing the highest response over 2 hours.*

FDA Label Image

Figure-4 (Rizatriptan Figure 4)

A line graph showing the estimated probability of medication or rescue over 24 hours post-dose for rizatriptan benzoate orally disintegrating tablets at 5 mg and 10 mg doses compared to placebo. The y-axis represents the probability percentage, while the x-axis shows hours post-dose from 0 to 24. Three lines chart the progression for placebo, 5 mg, and 10 mg dosage strengths.*

FDA Label Image

Rizatriptan Figure 5

A line graph comparing the percentage response over time for Rizatriptan Benzoate Orally Disintegrating Tablets versus Placebo. The x-axis represents hours post stage 2 dose (0.5 to 2.0 hours), and the y-axis shows percent response with 95% confidence intervals. The graph displays increasing response over time for both treatment and placebo, with Rizatriptan showing higher percent values.*

FDA Label Image

Rizatriptan Odt Usp 10mg 1x3s

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets USP 10 mg by Macleods Pharmaceuticals Limited. The label indicates a box containing 3 tablets (1 x 3 unit-dose tablets). It includes manufacturer details, patient dispensing instructions, storage conditions, and a barcode. The product is an oral tablet in orally disintegrating form.*

FDA Label Image

Rizatriptan Odt Usp 10mg 2x6ss

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets USP, 10 mg, by Macleods Pharmaceuticals Limited. The label indicates a prescription oral tablet in unit-dose blister packs, with a total of 12 tablets (2 x 6 unit-dose tablets). Instructions for opening the blister pack are illustrated, and storage conditions and manufacturer information are included.*

FDA Label Image

Rizatriptan Odt Usp 10mg 3x3s

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10 mg by Macleods Pharmaceuticals Limited. It features the product name, strength, dosage form as orally disintegrating tablets, and package size of 9 tablets (3 x 3 unit-dose tablets). The label includes storage instructions, a note about phenylalanine content, manufacturer details, and illustrated instructions for opening the blister pack.*

FDA Label Image

Rizatriptan Odt Usp 10mg 3x6s

The carton label for rizatriptan benzoate 10 mg orally disintegrating tablets, USP by Macleods Pharmaceuticals Limited. The package contains 18 tablets (3 x 6 unit-dose tablets). The label includes instructions for opening the blister pack, storage information, a barcode, and manufacturing details indicating Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd in India.*

FDA Label Image

Rizatriptan Odt Usp 10mg 6x3s

Label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10 mg from Macleods Pharmaceuticals Limited. The label shows 18 tablets in unit-dose packaging with instructions for opening the blister pack. It includes storage conditions, a barcode, manufacturer and labeler information, and prescription-only status.*

FDA Label Image

Rizatriptan Odt Usp 5mg 1x3s

Label for Rizatriptan Benzoate Orally Disintegrating Tablets USP 5 mg, 3 unit-dose tablets per pack, labeled for prescription use. Manufactured by Macleods Pharmaceuticals Ltd, India, for Macleods Pharma USA, Inc. Label includes barcode, storage instructions, and blister pack opening instructions.*

FDA Label Image

Rizatriptan Odt Usp 5mg 2x6ss

The carton label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP, 5 mg by Macleods Pharmaceuticals Limited. The package contains 12 tablets (2 x 6 unit-dose tablets). The label includes the product name, strength, dosage form, manufacturer details, instructions for opening the blister pack, and storage and dosage notes. The NDC listed is 33342-093-45.*

FDA Label Image

Rizatriptan Odt Usp 5mg 3x3s

The packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5 mg from Macleods Pharmaceuticals Limited. The label shows a bottle with 9 tablets (3 x 3 unit-dose tablets) designed for oral administration. It includes instructions for opening the blister pack, storage conditions, dosage note, and a barcode. The label is marked Rx only and shows the product is manufactured by Macleods Pharmaceuticals Ltd., India, for Macleods Pharma USA, Inc.*

FDA Label Image

Rizatriptan Odt Usp 5mg 3x6s

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5 mg by Macleods Pharmaceuticals Limited. The label shows the product name, strength (5 mg), dosage form (orally disintegrating tablets), package quantity (18 tablets, 3 x 6 unit-dose tablets), and manufacturer details. It includes instructions for opening the blister pack and storage conditions.*

FDA Label Image

Rizatriptan Odt Usp 5mg 6x3s

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5 mg by Macleods Pharmaceuticals Limited. The label shows the product name, strength, dosage form, the NDC number 33342-093-72, and the package contains 18 tablets (6 x 3 unit-dose tablets). Manufacturer and distributor details are included, along with tablet composition and storage instructions. Instructions for opening the blister pack are also depicted.*

FDA Label Image

Structure (Rizatriptan Structure)

Chemical structure of rizatriptan benzoate, illustrating the molecular arrangement of its active ingredient components, including the indole and benzoate groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.